Page 36 - Recursion Pharmaceuticals News Today

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) – Research analysts at KeyCorp issued their Q1 2024 earnings per share estimates for Recursion Pharmaceuticals in a research report issued to clients and investors on Monday, May 8th. KeyCorp analyst S. Schoenhaus expects that the company will earn ($0.33) per share for the quarter. The consensus estimate […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) – Equities researchers at KeyCorp issued their Q1 2024 earnings per share (EPS) estimates for shares of Recursion Pharmaceuticals in a report released on Monday, May 8th. KeyCorp analyst S. Schoenhaus expects that the company will earn ($0.33) per share for the quarter. The consensus estimate for Recursion […]

Recursion Pharmaceuticals is acquiring two Canada-based artificial intelligence startups, Cyclica and Valence. The “biology-first company” says both deals build up its capability to apply AI to the chemistry side of drug discovery.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) posted its earnings results on Monday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.01, MarketWatch Earnings reports. Recursion Pharmaceuticals had a negative return on equity of 53.07% and a negative net margin of 601.05%. The business had revenue […]

BioPharma

Entered into agreements to acquire Cyclica and Valence to bolster digital chemistry and generative AI capabilities in order to further create new chemical composition of matter for novel biological... | May 8, 2023

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) CEO Christopher Gibson sold 33,073 shares of the firm’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $4.71, for a total transaction of $155,773.83. Following the sale, the chief executive officer now directly owns 953,225 shares in the company, […]

The Artificial Intelligence (AI) in Medicine market is a rapidly growing segment of the healthcare industry that is expected to significantly transform the way healthcare is delivered in the future. AI technology has the potential to revolutionize healthcare by improving the accuracy, efficiency, and speed of medica...

Jackson Creek Investment Advisors LLC purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) during the 4th quarter, Holdings Channel reports. The firm purchased 77,011 shares of the company’s stock, valued at approximately $594,000. Several other large investors have also modified their holdings of the business. Baillie Gifford & Co. grew its […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) Director Blake Borgeson sold 8,885 shares of the firm’s stock in a transaction dated Tuesday, April 18th. The shares were sold at an average price of $5.93, for a total transaction of $52,688.05. Following the transaction, the director now directly owns 7,558,517 shares in the company, valued at […]